Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stomach Neoplasms | 10 | 2020 | 1333 | 2.740 |
Why?
|
Lymph Nodes | 7 | 2018 | 3474 | 1.180 |
Why?
|
Gastrectomy | 4 | 2018 | 663 | 1.040 |
Why?
|
Adenocarcinoma | 5 | 2020 | 6364 | 0.910 |
Why?
|
Neoadjuvant Therapy | 5 | 2020 | 2728 | 0.900 |
Why?
|
Pancreatic Neoplasms | 6 | 2020 | 5256 | 0.880 |
Why?
|
Lymph Node Excision | 5 | 2020 | 1261 | 0.810 |
Why?
|
Pancreatectomy | 4 | 2020 | 804 | 0.700 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2018 | 30 | 0.650 |
Why?
|
Neuroendocrine Tumors | 3 | 2018 | 594 | 0.620 |
Why?
|
Chemoprevention | 1 | 2018 | 319 | 0.540 |
Why?
|
Standard of Care | 1 | 2019 | 564 | 0.540 |
Why?
|
Cyclooxygenase 2 | 1 | 2018 | 611 | 0.530 |
Why?
|
Adenoma | 2 | 2018 | 2174 | 0.510 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11031 | 0.480 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2020 | 1634 | 0.470 |
Why?
|
Anticarcinogenic Agents | 2 | 2013 | 253 | 0.450 |
Why?
|
SEER Program | 6 | 2018 | 1508 | 0.440 |
Why?
|
Colonic Neoplasms | 3 | 2009 | 2541 | 0.420 |
Why?
|
Pancreaticoduodenectomy | 3 | 2020 | 503 | 0.410 |
Why?
|
Neoplasm Invasiveness | 6 | 2018 | 3616 | 0.380 |
Why?
|
Carcinoma | 1 | 2020 | 2375 | 0.320 |
Why?
|
Liver Neoplasms | 6 | 2020 | 4253 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2020 | 9239 | 0.290 |
Why?
|
Mortality | 1 | 2018 | 2864 | 0.290 |
Why?
|
Laparoscopy | 1 | 2018 | 2151 | 0.280 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8642 | 0.270 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2019 | 1770 | 0.260 |
Why?
|
Length of Stay | 1 | 2018 | 6309 | 0.260 |
Why?
|
Hepatectomy | 2 | 2020 | 550 | 0.250 |
Why?
|
Proportional Hazards Models | 9 | 2020 | 12354 | 0.250 |
Why?
|
Databases, Factual | 5 | 2019 | 7729 | 0.250 |
Why?
|
Patient Readmission | 1 | 2018 | 3114 | 0.240 |
Why?
|
Aged | 31 | 2020 | 163280 | 0.240 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2020 | 2214 | 0.240 |
Why?
|
Prognosis | 12 | 2020 | 29063 | 0.240 |
Why?
|
Survival Rate | 9 | 2020 | 12788 | 0.240 |
Why?
|
Survival Analysis | 6 | 2019 | 10252 | 0.240 |
Why?
|
Sulfonamides | 1 | 2013 | 1938 | 0.230 |
Why?
|
Aged, 80 and over | 15 | 2020 | 57776 | 0.230 |
Why?
|
Breast Diseases | 2 | 2004 | 443 | 0.230 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2017 | 340 | 0.230 |
Why?
|
Hepatitis B | 2 | 2020 | 695 | 0.230 |
Why?
|
Pyrazoles | 1 | 2013 | 1972 | 0.220 |
Why?
|
Middle Aged | 34 | 2020 | 213383 | 0.220 |
Why?
|
Lymphatic Metastasis | 4 | 2018 | 2924 | 0.200 |
Why?
|
Male | 35 | 2020 | 350118 | 0.200 |
Why?
|
Female | 40 | 2020 | 380194 | 0.200 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3479 | 0.190 |
Why?
|
Sarcoma | 3 | 2017 | 1897 | 0.190 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2020 | 129 | 0.180 |
Why?
|
Age Factors | 6 | 2019 | 18370 | 0.180 |
Why?
|
Sorting Nexins | 1 | 2020 | 23 | 0.180 |
Why?
|
Retrospective Studies | 20 | 2020 | 77449 | 0.180 |
Why?
|
Peptide Elongation Factor 1 | 1 | 2020 | 40 | 0.180 |
Why?
|
Peripheral Vascular Diseases | 3 | 2008 | 550 | 0.180 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 6773 | 0.170 |
Why?
|
Treatment Outcome | 10 | 2020 | 63114 | 0.160 |
Why?
|
Quality Indicators, Health Care | 1 | 2009 | 1831 | 0.160 |
Why?
|
Humans | 46 | 2020 | 744343 | 0.150 |
Why?
|
Colon | 2 | 2017 | 1772 | 0.150 |
Why?
|
Portal Vein | 1 | 2020 | 437 | 0.150 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2004 | 1101 | 0.140 |
Why?
|
Myeloid Cells | 1 | 2020 | 810 | 0.130 |
Why?
|
Taiwan | 1 | 2017 | 496 | 0.130 |
Why?
|
Vascular Surgical Procedures | 4 | 2008 | 1475 | 0.130 |
Why?
|
United States | 8 | 2020 | 69872 | 0.130 |
Why?
|
Adrenal Glands | 1 | 2017 | 546 | 0.130 |
Why?
|
Hospitals, University | 1 | 2017 | 571 | 0.130 |
Why?
|
Ubiquitin | 1 | 2020 | 852 | 0.120 |
Why?
|
Hemangiosarcoma | 1 | 2017 | 239 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6538 | 0.120 |
Why?
|
China | 1 | 2020 | 2248 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2020 | 987 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15519 | 0.120 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 67 | 0.120 |
Why?
|
Receptor, erbB-3 | 1 | 2014 | 142 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1338 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 547 | 0.110 |
Why?
|
Estrogen Receptor beta | 1 | 2013 | 175 | 0.110 |
Why?
|
Tumor Burden | 1 | 2018 | 1915 | 0.110 |
Why?
|
Receptor, IGF Type 1 | 1 | 2014 | 390 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 604 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2018 | 12245 | 0.100 |
Why?
|
Cadherins | 1 | 2016 | 907 | 0.100 |
Why?
|
Extremities | 2 | 2014 | 865 | 0.100 |
Why?
|
Endosonography | 1 | 2015 | 610 | 0.100 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1032 | 0.100 |
Why?
|
Risk Assessment | 8 | 2019 | 23338 | 0.090 |
Why?
|
Cholangiocarcinoma | 1 | 2016 | 516 | 0.090 |
Why?
|
Adult | 20 | 2020 | 214055 | 0.090 |
Why?
|
Receptor, Insulin | 1 | 2014 | 846 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2014 | 578 | 0.090 |
Why?
|
Dermatofibrosarcoma | 1 | 2010 | 63 | 0.090 |
Why?
|
Liver Transplantation | 1 | 2020 | 2119 | 0.090 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 949 | 0.090 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 577 | 0.090 |
Why?
|
Catheter Ablation | 2 | 2017 | 2758 | 0.090 |
Why?
|
Postoperative Complications | 4 | 2020 | 15295 | 0.090 |
Why?
|
Linkage Disequilibrium | 1 | 2013 | 1997 | 0.080 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3586 | 0.080 |
Why?
|
Disease-Free Survival | 3 | 2020 | 6895 | 0.080 |
Why?
|
Young Adult | 6 | 2018 | 56430 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2759 | 0.080 |
Why?
|
Mohs Surgery | 1 | 2010 | 197 | 0.080 |
Why?
|
Registries | 2 | 2017 | 8089 | 0.080 |
Why?
|
Proctoscopy | 1 | 2007 | 42 | 0.080 |
Why?
|
Preoperative Care | 2 | 2015 | 2250 | 0.070 |
Why?
|
Hepatitis B, Chronic | 1 | 2011 | 393 | 0.070 |
Why?
|
Breast Neoplasms | 4 | 2017 | 20822 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2015 | 2942 | 0.070 |
Why?
|
Brachytherapy | 1 | 2014 | 1248 | 0.070 |
Why?
|
Prospective Studies | 4 | 2018 | 53288 | 0.070 |
Why?
|
Probability | 2 | 2009 | 2505 | 0.070 |
Why?
|
Carcinoid Tumor | 1 | 2007 | 235 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 2007 | 0.070 |
Why?
|
Germ-Line Mutation | 1 | 2013 | 1788 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2849 | 0.070 |
Why?
|
Sputum | 1 | 2007 | 476 | 0.060 |
Why?
|
Skin Neoplasms | 2 | 2017 | 5686 | 0.060 |
Why?
|
Limb Salvage | 1 | 2007 | 433 | 0.060 |
Why?
|
Vascular Patency | 1 | 2007 | 886 | 0.060 |
Why?
|
Saphenous Vein | 1 | 2007 | 532 | 0.060 |
Why?
|
Macula Lutea | 1 | 2005 | 151 | 0.060 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2007 | 274 | 0.060 |
Why?
|
Antigens, CD | 1 | 2014 | 4026 | 0.060 |
Why?
|
Logistic Models | 1 | 2018 | 13408 | 0.060 |
Why?
|
Paroxetine | 1 | 2004 | 182 | 0.060 |
Why?
|
Estrogen Receptor Modulators | 1 | 2003 | 61 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2013 | 9959 | 0.050 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2005 | 245 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7186 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2017 | 39050 | 0.050 |
Why?
|
Cohort Studies | 3 | 2020 | 40561 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11524 | 0.050 |
Why?
|
Nerve Fibers | 1 | 2005 | 687 | 0.050 |
Why?
|
Optic Disk | 1 | 2005 | 400 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2009 | 6365 | 0.050 |
Why?
|
Ligation | 1 | 2020 | 453 | 0.040 |
Why?
|
Retinal Ganglion Cells | 1 | 2005 | 770 | 0.040 |
Why?
|
Lower Extremity | 1 | 2007 | 1158 | 0.040 |
Why?
|
Irritable Bowel Syndrome | 1 | 2004 | 445 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2020 | 376 | 0.040 |
Why?
|
Tamoxifen | 1 | 2003 | 981 | 0.040 |
Why?
|
Carcinoma in Situ | 1 | 2004 | 806 | 0.040 |
Why?
|
Protein Stability | 1 | 2020 | 557 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2007 | 1206 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2002 | 2242 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14722 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2009 | 15076 | 0.030 |
Why?
|
Doxorubicin | 1 | 2002 | 2234 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2013 | 21746 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2017 | 341 | 0.030 |
Why?
|
MicroRNAs | 1 | 2011 | 3752 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17446 | 0.030 |
Why?
|
Glaucoma | 1 | 2005 | 1159 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10397 | 0.030 |
Why?
|
Depressive Disorder | 1 | 2008 | 3748 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2020 | 1758 | 0.030 |
Why?
|
New York | 2 | 2008 | 886 | 0.030 |
Why?
|
Morbidity | 1 | 2020 | 1769 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12261 | 0.030 |
Why?
|
Hepatitis B virus | 1 | 2018 | 513 | 0.030 |
Why?
|
Aberrant Crypt Foci | 1 | 2013 | 12 | 0.030 |
Why?
|
Pancreas | 1 | 2020 | 1686 | 0.030 |
Why?
|
Paneth Cells | 1 | 2013 | 99 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3689 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1781 | 0.030 |
Why?
|
Coronary Disease | 1 | 2008 | 6077 | 0.030 |
Why?
|
Smad4 Protein | 1 | 2013 | 163 | 0.030 |
Why?
|
Incidence | 2 | 2017 | 20947 | 0.030 |
Why?
|
Colectomy | 1 | 2017 | 683 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2203 | 0.030 |
Why?
|
Tomography, Optical Coherence | 1 | 2005 | 2657 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20129 | 0.030 |
Why?
|
Mastectomy, Segmental | 1 | 2017 | 956 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3557 | 0.030 |
Why?
|
Nephrectomy | 1 | 2017 | 1050 | 0.030 |
Why?
|
Neoplasms | 1 | 2020 | 21683 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2886 | 0.020 |
Why?
|
Risk Factors | 5 | 2020 | 72290 | 0.020 |
Why?
|
Apoptosis | 2 | 2020 | 9727 | 0.020 |
Why?
|
Biopsy | 1 | 2003 | 6756 | 0.020 |
Why?
|
ROC Curve | 2 | 2011 | 3527 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16689 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4217 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1866 | 0.020 |
Why?
|
Algorithms | 2 | 2008 | 13881 | 0.020 |
Why?
|
Safety | 1 | 2014 | 1186 | 0.020 |
Why?
|
Frozen Sections | 1 | 2010 | 155 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2007 | 15540 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 7181 | 0.020 |
Why?
|
Signal Transduction | 3 | 2020 | 23403 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2013 | 783 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4851 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1356 | 0.020 |
Why?
|
Phenazines | 1 | 2007 | 58 | 0.020 |
Why?
|
Gentian Violet | 1 | 2007 | 31 | 0.020 |
Why?
|
Graft Rejection | 1 | 2020 | 4397 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 1941 | 0.020 |
Why?
|
Depression | 1 | 2007 | 7766 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4186 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2459 | 0.020 |
Why?
|
Time Factors | 2 | 2007 | 40075 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11366 | 0.020 |
Why?
|
Venous Insufficiency | 1 | 2007 | 103 | 0.020 |
Why?
|
Popliteal Artery | 1 | 2008 | 317 | 0.020 |
Why?
|
Hospitals, Veterans | 1 | 2008 | 404 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2010 | 973 | 0.020 |
Why?
|
Immunotherapy | 1 | 2020 | 4445 | 0.020 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2007 | 768 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2014 | 2416 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10481 | 0.010 |
Why?
|
Femoral Artery | 1 | 2008 | 845 | 0.010 |
Why?
|
Leg | 1 | 2008 | 1116 | 0.010 |
Why?
|
Visual Field Tests | 1 | 2005 | 383 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 2013 | 3036 | 0.010 |
Why?
|
Diagnostic Tests, Routine | 1 | 2008 | 783 | 0.010 |
Why?
|
Treatment Failure | 1 | 2007 | 2618 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1654 | 0.010 |
Why?
|
Medical Records Systems, Computerized | 1 | 2007 | 1205 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3567 | 0.010 |
Why?
|
Dietary Fiber | 1 | 2004 | 760 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81183 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2016 | 8428 | 0.010 |
Why?
|
Adolescent | 3 | 2017 | 85781 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2014 | 5172 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13284 | 0.010 |
Why?
|
Intraocular Pressure | 1 | 2005 | 1270 | 0.010 |
Why?
|
Visual Fields | 1 | 2005 | 1047 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2011 | 3086 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 4982 | 0.010 |
Why?
|
Anesthesia | 1 | 2008 | 1561 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2010 | 2734 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 4933 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 29786 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 21827 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 9438 | 0.010 |
Why?
|
Odds Ratio | 1 | 2008 | 9849 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8340 | 0.010 |
Why?
|
Animals | 2 | 2020 | 168757 | 0.010 |
Why?
|
Intensive Care Units | 1 | 2007 | 3679 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10943 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2004 | 12026 | 0.010 |
Why?
|
Prevalence | 1 | 2007 | 15226 | 0.010 |
Why?
|
Stroke | 1 | 2008 | 9981 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2005 | 25043 | 0.000 |
Why?
|